Skip to main content

The Editorial Board recommends

Session recommendation

The CAROLINA trial: First results of the cardiovascular outcomes trial comparing linagliptin vs. glimepiride

Monday June 10, 16:30–18:30. Room W-3001, Moscone Center, San Francisco, California

Clinical trial overview | Expert opinion editorial 

  1. Introduction and study background. Julio Rosenstock, MD
  2. Study design, statistical plan, and baseline characteristics. Mark Espeland, PhD
  3. Metabolic and body weight outcomes. Steven E. Kahn, MB, ChB
  4. Cardiovascular, mortality, and hospitalization outcomes. Nikolaus Marx, MD, FESC, FAHA
  5. Adverse events and hypoglycemia analyses. Bernard Zinman, CM, MD
  6. Clinical implications for the cardiologist and diabetologists. Darren K. McGuire, MD, MHSc, Bernard Zinman, CM, MD
  7. Independent commentator. Matthew C. Riddle, MD
  8. Final Remarks and acknowledgements. Julio Rosenstock, MD

The diabetes community is anxiously awaiting the results of this cardiovascular outcome trial. As the only active comparator trial, we are hoping to learn more about the use of a sulfonlyurea in high-risk patients when compared to a DPP-4 inhibitor.

– Lori Berard, Nurse Consultant and Diabetes Educator

Session recommendation

Making a difference in five minutes—Interventions in diabetes for anyone

Saturday June 8, 13:45–15:45. Room S-203, Moscone Center, San Francisco, California 

  1. Richard R. Rubin award lecture. Frank J. Snoek, PhD
  2. Overcoming psychological insulin resistance. William Polonsky, PhD, CDE
  3. Innovative simple intervention to improve adherence. Olga T. Gupta, MD
  4. Strategies around weight loss in diabetes. David Flomo, MPH, MSW, RSW
  5. Management of diabetes burnout. Susan Guzman, PhD

We need to improve the way we delivery care for our patients with diabetes, but time is always a factor. I'm looking forward to hearing how we can be more effective in five minutes!

– Lori Berard, Nurse Consultant and Diabetes Educator

This session is 2 hours long, but each second should be worth it. All of us who deal with people living with diabetes will gain from the expert opinions presented here. Using insulin, ensuring adherence, achieving weight loss, and managing diabetes burnout will figure in this session. The speakers will provide insight which will help translate current knowledge into effective clinical practice.

– Sanjay Kalra, Diabetologist

Session recommendation

Cardiovascular and renal protection in diabetes: emphasis on SGLT2 inhibitors and GLP-1 receptor agonists

Saturday June 8, 13:45–15:45. Room B-Hall E, Moscone Center, San Francisco, California

  1. ​​​​​​​Renal effects of GLP-1 receptor agonists: from basic mechanisms to clinical data. Julie A. Lovshin, MD, PhD
  2. Cardiovascular effects of GLP-1 receptor agonists: From basic mechanisms to clinical data. Jens J. Holst, MD, DMSc
  3. Renal effects of SGLT2 Inhibitors: From basic mechanisms to clinical data. David C. Wheeler, MD
  4. Cardiovascular effects of SGLT2 inhibitors:  From basic mechanisms to clinical data. Javed Butler, MD, MPH, MBA

This session links directly to the recent ask the expert videos we produced with Dr Katherine Tuttle [Nephrologist and Endocrinologist], regarding the impact of renal impairment on cardiovascular disease. We should really be discussing "cardio-renal disease" rather than "cardiovascular disease".

– Jay Shubrook, Primary Care Physician

Session recommendation

The Vitamin D and type 2 diabetes (D2d) study: A multicenter randomized controlled trial for diabetes prevention

Friday June 7, 11:30–12:30. Room S157, Moscone Center, San Francisco, California

  1. Rationale and study design. Myrlene A. Staten, MD
  2. Recruitment, retention, and baseline characteristics. Erin S. Leblanc, MD, MPH
  3. Outcomes. Anastassios G. Pittas, MD, MS

The D2d trial is of particular interest due to a growing body of evidence which suggests that glucose and insulin metabolism may have farther-reaching effects on health and nutrition than previously thought. There now appears to be a greater understanding as to why so many patients with type 2 diabetes have vitamin D deficiency, and we need to determine if it's causative or as a result of insulin resistance​​​​​​​.

– Jay Shubrook, Primary Care Physician

Session recommendation

ADA nutrition therapy for adults with diabetes: 2019 consensus paper

Saturday June 8: 8:00–10:00. Room S-203, Moscone Center, San Francisco, California

  1. Are nutrition and diabetes education interventions effective in improving outcomes? Janice MacLeod, MA, RDN, CDE
  2. What’s the best eating pattern for adults with diabetes? William S. Yancy, Jr., MD, MHS
  3. What’s the role of weight loss in overweight/obese adults with diabetes? W. Timothy Garvey, MD
  4. What’s the best approach for optimizing glycemic control? (macronutrients and insulin dosing.) Ka Hei Karen Lau, MS, RD, LDN, CDE
  5. What’s the role of nutrition in diabetes prevention? Christopher D. Gardner, PhD
  6. Translation to practice. Kelly M. Rawlings, MS

Ever-changing – always evolving – nutritional recommendation are one of the cornerstones of diabetes management. Evolving evidence of the benefit of different dietary patterns will help us to guide our patients in the healthy lifestyle behavior.

– Lori Berard, Nurse Consultant and Diabetes Educator

Session recommendation

Oral semaglutide: The PIONEER program trials

Tuesday June 11, 9:45–11:45. Room N-Hall E, Moscone Center, San Francisco, California

Clinical trial overview | PIONEER 2 and 4 news

  1. Introduction. John B. Buse, MD, PhD
  2. Oral semaglutide: How well does it work and in what settings? Vanita R. Aroda, MD
  3. Oral semaglutide: How does it compare to alternatives? Richard E. Pratley, MD
  4. PIONEER 6: Trial design and baseline characteristics. Stephen C. Bain, MA, MD, FRCP
  5. PIONEER 6: Cardiovascular outcomes. Mansoor Husain, MD, FRCPC
  6. PIONEER 6: Metabolic and safety outcomes. Ofri Mosenzon, MD, MSc
  7. Summary. John B. Buse, MD, PhD
  8. Independent commentary. Vivian Fonseca, MD

An exciting time for the GLP-1RA class with the introduction of the first oral preparation. The PIONEER program will provide safety and efficacy data across a broad range of patients as well as provide us with insight into the cardiovascular safety in the PIONEER 6 trial.

– Lori Berard, Nurse Consultant and Diabetes Educator


Session recommendation

Paternal programming: I’m your papa

Friday June 7, 14:00–16:00. Room S-157, Moscone Center, San Francisco, California

  1. Evidence and mechanisms for paternal epigenetic regulation of developmental origins of health and disease. Elvira Isganaitis, MD, MPH
  2. ​​​​​​​Obesity and bariatric surgery drive epigenetic variation of spermatozoa (human). Ida Donkin, MD, PhD
  3. Preconception diet or exercise intervention in obese fathers normalizes sperm microRNA profile and metabolic syndrome in female offspring (mouse). Nicole O. McPherson, PhD 
  4. Paternal long-term exercise programs offspring for low energy expenditure and increased risk for obesity in mice. P. Darrel Neufer, PhD
  5. Cold-induced epigenetic programming of the sperm enhances brown adipose tissue activity in the offspring (human and mouse). Christian Wolfrum, PhD

The session seems interesting for clinicians, educators and researchers. Findings discussed in talks at this symposium will stimulate us to view men as important contributors to the health of their offspring. A focus on pre-conception counselling in males should help us understand and address the epidemic of diabetes and other metabolic disease.

Sanjay Kalra, Diabetologist

Session recommendation

Once-weekly dulaglutide and major cardiovascular events: Results of the REWIND trial

Sunday June 8, 16:30–18:30. Room W-3001, Moscone Center, San Francisco, California

Read our clinical trial overview

  1. Introduction and research question. Gilles R. Dagenais, MD
  2. Background. Rafael Diaz, MD
  3. Design and baseline characteristics and secondary outcomes testing. Matthew C. Riddle, MD
  4. Study conduct (adherence, retention, A1c effect, weight, etc.) Helen Colhoun, MD
  5. Cardiovascular outcomes. Hertzel C. Gerstein, MD, MSc, FRCPC
  6. Safety. Jeffrey L. Probstfield, MD
  7. Summary and implications. Lars Rydén, MD, PhD
  8. Independent commentary. Sophia Zoungas, MBBS (Hons), PhD, FRACP

Top-line results for the REWIND trial have stated that superiority was achieved.  We are keenly awaiting the full report to fully understand the benefit of a GLP-1RAs in a population of people without established cardiovascular disease. Unlike prior trials with GLP-1RAs the majority of this participants do not have atherosclerotic cardiovascular disease.

– Lori Berard, Nurse Consultant and Diabetes Educator